NSE · CLSL
Crop Life Science Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹209 Cr with net profit ₹7 Cr — a 3.18% net margin, versus 2.92% the period before.
Shareholding
As of 2026-03-31
- Promoter70.01%
- Public29.99%
1,060 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.36× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pesticides / Agrochemicals - Indian · ranked #1 of 29 by market cap · medians across 27 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| UPL Limited | ₹48,432 Cr | 24.47 | 1.4 | 5.54% | 3.83% |
| PI Industries Ltd. | ₹34,231 Cr | 31.69 | 3.05 | 11.76% | 17.88% |
| Sumitomo Chemical India Ltd. | ₹23,645 Cr | 41.37 | 6.98 | 16.02% | 17.86% |
| Sharda Cropchem Ltd. | ₹6,956 Cr | 11.11 | 2.22 | 21.71% | 11.69% |
| Dhanuka Agritech Ltd. | ₹4,358 Cr | 14.94 | 3.11 | 21.17% | 14.59% |
| Rallis India Ltd. | ₹3,941 Cr | 17.26 | 1.93 | 9.88% | 7.22% |
| NACL Industries Limited | ₹3,701 Cr | 142.32 | 5.42 | 2.49% | 0.81% |
| Bhagiradha Chemicals & Industries Ltd. | ₹3,327 Cr | 121.04 | 4.76 | 2.6% | 4.53% |
| Bharat Rasayan Ltd. | ₹1,932 Cr | 13.21 | 1.52 | 11.43% | 11.92% |
| Insecticides India Ltd. | ₹1,767 Cr | 14.12 | 1.45 | 11.42% | 6.08% |
| Crop Life Science Limited(this company) | — | 20.34 | 1.67 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashCrop Life Science Limited (CLSL) is listed on the Indian markets with a market capitalization of Rs 83 Cr. The company reported revenue of Rs 201.61 Cr and profit per share of Rs 3.27 as of March 2025. The promoter holding stands at 70.0117% as of March 2026.
Positives
- +Revenue increased by 0.44% to Rs 201.6073 Cr in March 2025.
- +EBITDA increased to Rs 12.5489 Cr in March 2025 from Rs 11.5002 Cr in March 2024.
- +Promoter holding of 70.0117% as of March 2026 indicates significant control.
Negatives
- −Net profit decreased by 2.19% from Rs 6.0233 Cr in March 2024 to Rs 5.8916 Cr in March 2025.
- −Promoter pledge of 2.08% was introduced in March 2025, after being 0% in March 2024.
- −The company is under ST-ASM surveillance, indicating regulatory monitoring due to certain parameters.
Financial Performance
Crop Life Science Limited reported revenue of Rs 201.6073 Cr in March 2025, a 0.44% increase from Rs 200.7162 Cr in March 2024. Net profit for March 2025 was Rs 5.8916 Cr, down from Rs 6.0233 Cr in March 2024. The company's EPS was Rs 3.27 in March 2025.
Profitability & Returns
The company's ROCE is 11.96%. EBITDA for March 2025 was Rs 12.5489 Cr, an increase from Rs 11.5002 Cr in March 2024. The company's PE ratio is 14.73 based on its EPS of Rs 4.08.
Balance Sheet
Crop Life Science Limited has a debt-to-equity ratio of 0.53. The book value per share is Rs 49.8. The company's market capitalization is Rs 83 Cr.
Ownership & Pledges
This is consistent with promoter holding seen in March 2025, Sep 2025, and Mar 2024. Public shareholding is 29.9883%. 2.08% of promoter shares are pledged, corresponding to 150,000 shares of Sumitaben Rajeshkumar Lunagariya and 100,000 shares of Vijayaben A Lunagaria pledged as of March 2026.
Regulatory & Surveillance
The company is currently under ST-ASM surveillance, specifically ASM 1.
Data as of — price: 2026-09-11 · financials: Mar 26 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.